Sure, keep in mind this is just my rough calculations and based on hypothetical scenarios:
$75M Current Products launched
$75M 5 ANDAs launching this is a conservative 7.5% market share (APAP/Oxy, Hydro/APAP, Methadone, Apap and Codeine, methotrexate)
$860M, this is the wild card, 20% of the current 4.3B, with the drug being in shortage the price should stay elevated and if we have a new API with no supply
issues.
$1.01B in sales assume a 35% profit margin, assumptions again, I think this may be higher as the margins for Vyvanse will be better, but I am going conservative
$353.5M/Shares Outstanding
$0.333c/share
PE 25 is $8.33
PE 35 is $11.67
This is all hypothetical and of course if everything goes perfect but shows the potential and keep in mind this does not include any new drugs filed and in the pipeline. This is why I am excited!! Fun to play with numbers, time will tell!!
Market Data 
Markets 
AI
